Genmab A/S ADR (GMAB): Price and Financial Metrics

Genmab A/S ADR (GMAB): $26.03

0.15 (+0.58%)

POWR Rating

Component Grades








Add GMAB to Watchlist
Sign Up

Industry: Biotech




#8 of 347

in industry

GMAB Price/Volume Stats

Current price $26.03 52-week high $42.72
Prev. close $25.88 52-week low $25.38
Day low $25.77 Volume 579,700
Day high $26.05 Avg. volume 568,047
50-day MA $28.39 Dividend yield N/A
200-day MA $30.46 Market Cap 17.21B

GMAB Stock Price Chart Interactive Chart >

Genmab A/S ADR (GMAB) Company Bio

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in UtrechtThe Netherlands, Genmab U.S., Inc. in PrincetonUSA, and Genmab K.K. in TokyoJapan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. (Source:Wikipedia)

GMAB Latest News Stream

Event/Time News Detail
Loading, please wait...

GMAB Latest Social Stream

Loading social stream, please wait...

View Full GMAB Social Stream

Latest GMAB News From Around the Web

Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and ASH Data Review Meeting today, December 12, 2023 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click An archive of the webcast will be avai

Yahoo | December 12, 2023

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

COPENHAGEN, Denmark, December 09, 2023--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate of 63 percent and minimal residual disease (MRD) negativity rate of 67 percent in patients with relapsed/refractory (R/R) foll

Yahoo | December 9, 2023

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the st

Yahoo | December 9, 2023

HRMY or GMAB: Which Is the Better Value Stock Right Now?

HRMY vs. GMAB: Which Stock Is the Better Value Option?

Yahoo | December 7, 2023

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,106 shares at DKK 1,025.00,3,453 shares at DKK 1,145.00,300 shares at DKK 1,147.50,85 shares at DKK 1,161.00,7

Yahoo | December 5, 2023

Read More 'GMAB' Stories Here

GMAB Price Returns

1-mo -7.04%
3-mo -13.18%
6-mo -17.81%
1-year -32.18%
3-year -37.98%
5-year 43.77%
YTD -18.25%
2023 -24.87%
2022 7.13%
2021 -2.71%
2020 82.09%
2019 35.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!